Poster – Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotypic screening – Application on metabolic diseases

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.

Ask for high quality link by putting your email below

Ask for high quality link by putting your email below

View and download on Slideshare (low quality) https://www.slideshare.net/hcspharma/poster-developmentandautomation-of-3d-innovativehipscbased-liver-organoidsincluding-the-microenvironment-for-phenotypic-screening-application-on-metabolic-diseases